WATERTOWN, Mass.--(BUSINESS WIRE)--Jan. 17, 2006--Acusphere, Inc. (NASDAQ: ACUS) today announced that the Journal of Controlled Release recently published a research paper describing its proprietary porous microparticle technology and AI-700, an ultrasound contrast agent for use in echocardiography. AI-700 is Acusphere’s lead product candidate and is currently in Phase 3 clinical trials. The paper is entitled “Porous PLGA microparticles: AI-700, an intravenously administered ultrasound contrast agent for use in echocardiography”. The Journal of Controlled Release is a respected peer reviewed source for innovative and original research on the topics of controlled release and delivery of drugs and biologically active agents.
